MiRNA-20a targets TXNIP to inhibit the activation of NLRP3, ASC and caspase-1 in adjuvant-induced arthritis FLS and to suppress the secretion of IL-1 and MMP-1. Here, TXNIP is linked to arthritic joint disease.